354 related articles for article (PubMed ID: 22108823)
41. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
42. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
[TBL] [Abstract][Full Text] [Related]
43. Targeting ALCAM in the cryo-treated tumour microenvironment successfully induces systemic anti-tumour immunity.
Kudo-Saito C; Fuwa T; Kawakami Y
Eur J Cancer; 2016 Jul; 62():54-61. PubMed ID: 27208904
[TBL] [Abstract][Full Text] [Related]
44. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
[TBL] [Abstract][Full Text] [Related]
45. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.
Jenq RR; Curran MA; Goldberg GL; Liu C; Allison JP; van den Brink MR
PLoS One; 2012; 7(4):e35222. PubMed ID: 22493742
[TBL] [Abstract][Full Text] [Related]
46. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
[TBL] [Abstract][Full Text] [Related]
47. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model.
Yoshimoto Y; Suzuki Y; Mimura K; Ando K; Oike T; Sato H; Okonogi N; Maruyama T; Izawa S; Noda SE; Fujii H; Kono K; Nakano T
PLoS One; 2014; 9(3):e92572. PubMed ID: 24686897
[TBL] [Abstract][Full Text] [Related]
48. Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer.
Youlin K; Li Z; Xiaodong W; Xiuheng L; Hengchen Z
Clin Dev Immunol; 2012; 2012():439235. PubMed ID: 22312406
[TBL] [Abstract][Full Text] [Related]
49. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
50. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
51. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
52. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
Fassò M; Waitz R; Hou Y; Rim T; Greenberg NM; Shastri N; Fong L; Allison JP
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3509-14. PubMed ID: 18303116
[TBL] [Abstract][Full Text] [Related]
53. CTLA-4 engagement and regulatory CD4+CD25+ T cells independently control CD8+-mediated responses under costimulation blockade.
Coenen JJ; Koenen HJ; van Rijssen E; Boon L; Joosten I; Hilbrands LB
J Immunol; 2006 May; 176(9):5240-6. PubMed ID: 16621989
[TBL] [Abstract][Full Text] [Related]
54. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
[TBL] [Abstract][Full Text] [Related]
55. Cytotoxic T-lymphocyte antigen 4 blockade augments the T-cell response primed by attenuated Listeria monocytogenes resulting in more rapid clearance of virulent bacterial challenge.
Rowe JH; Johanns TM; Ertelt JM; Lai JC; Way SS
Immunology; 2009 Sep; 128(1 Suppl):e471-8. PubMed ID: 19191906
[TBL] [Abstract][Full Text] [Related]
56. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
57. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
58. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.
Ruocco MG; Pilones KA; Kawashima N; Cammer M; Huang J; Babb JS; Liu M; Formenti SC; Dustin ML; Demaria S
J Clin Invest; 2012 Oct; 122(10):3718-30. PubMed ID: 22945631
[TBL] [Abstract][Full Text] [Related]
59. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
Kim EY; Lee EN; Lee J; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Joh JW; Kim SJ
Exp Mol Med; 2006 Jun; 38(3):284-94. PubMed ID: 16819287
[TBL] [Abstract][Full Text] [Related]
60. Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4
Zaidi N; Quezada SA; Kuroiwa JMY; Zhang L; Jaffee EM; Steinman RM; Wang B
Ann N Y Acad Sci; 2019 Jun; 1445(1):62-73. PubMed ID: 30945313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
